Floatz logo

FLUTICASONE

Lung Neuroendocrine Neoplasm

Roswell Park Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Lung Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
FOSLINANIB
TaiRx, Inc.
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC
Sargramostim
Roswell Park Cancer Institute
Phase 2CCC
Survaxm
Roswell Park Cancer Institute
Phase 2CCC
FILGRASTIM
Roswell Park Cancer Institute
Phase 2CCC
Ifa
Roswell Park Cancer Institute
Phase 2CCC

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →